BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33035922)

  • 1. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
    Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
    Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
    Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
    Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 as privileged target in drug discovery: A perspective.
    Pulya S; Amin SA; Adhikari N; Biswas S; Jha T; Ghosh B
    Pharmacol Res; 2021 Jan; 163():105274. PubMed ID: 33171304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
    Shen S; Kozikowski AP
    Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
    [No Abstract]   [Full Text] [Related]  

  • 8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
    Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
    Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of thiol-based histone deacetylase 6 inhibitors.
    Guo Z; Zhang Y; Bao Y; Huang Z; Gu X; Wang G; Li J
    Chem Biol Drug Des; 2022 Jul; 100(1):90-107. PubMed ID: 35404520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
    Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
    Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
    Molecules; 2022 May; 27(10):. PubMed ID: 35630812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.